Journal of thrombosis and haemostasis : JTH · 2026
An interactive human PROS1 variants database provides novel insights into the genetics and phenotypes of inherited protein S deficiency.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hou Zepeng, Liu Fangni, Dong Shixia, Guo Yiming, Yu Xiaowei, Ai Li-Jiezhuo, Zhang Mingshuo, Kang Jingxuan, Jiang Bo, Dong Yanyan, Zhao Meng, Pan Jiahui, Zhang Shujuan, Zhao Wenran, Wang Wei, Hao Dapeng, Shen Guomin
Аннотация
BACKGROUND: The lack of an interactive PROS1 variant database has impeded efficient research on inherited protein S deficiency (PSD).
OBJECTIVES: We aimed to develop an interactive PROS1 variant database for studying PSD epidemiology, genotype-phenotype correlations, and variant pathogenicity, thereby improving thrombotic risk prediction and clinical decision-making.
METHODS: We constructed an interactive database by systematically collating inherited PSD data from PubMed. The American College of Medical Genetics and Genomics classification was performed to explore variant pathogenicity. Statistical analyses were performed to investigate the epidemiology, clinical characteristics, genotype-phenotype correlations, and thrombosis risk assessment in PSD.
RESULTS: The database comprises 520 unique PROS1 variants identified from 2177 individuals with PSD, including 88 biallelic variant (BV) cases and 2089 monoallelic variant (MV) cases. More than 91% of variants are pathogenic or likely pathogenic based on the American College of Medical Genetics and Genomics classification. Certain variants demonstrate ethnic or geographic specificity. While the spectra of clinical presentations are similar between BV and MV individuals, BV carriers have a significantly earlier onset age. In BV individuals, total protein S (PS) and free PS levels, but not PS activity, show a correlation with the first-onset age. Notably, total PS in type III MV individuals is well correlated with their first-onset age, and these cases show a significantly lower frequency of symptoms and recurrent/multiple episodes, as well as later first-onset age. Furthermore, coexistence of other thrombophilia factors increases thrombosis risk of MV individuals.
CONCLUSION: This database provided a valuable resource for retrieving pathogenic PROS1 variants and associated clinical data, enhancing our understanding of thrombotic risk in PSD and facilitating precision medicine for PSD.
OBJECTIVES: We aimed to develop an interactive PROS1 variant database for studying PSD epidemiology, genotype-phenotype correlations, and variant pathogenicity, thereby improving thrombotic risk prediction and clinical decision-making.
METHODS: We constructed an interactive database by systematically collating inherited PSD data from PubMed. The American College of Medical Genetics and Genomics classification was performed to explore variant pathogenicity. Statistical analyses were performed to investigate the epidemiology, clinical characteristics, genotype-phenotype correlations, and thrombosis risk assessment in PSD.
RESULTS: The database comprises 520 unique PROS1 variants identified from 2177 individuals with PSD, including 88 biallelic variant (BV) cases and 2089 monoallelic variant (MV) cases. More than 91% of variants are pathogenic or likely pathogenic based on the American College of Medical Genetics and Genomics classification. Certain variants demonstrate ethnic or geographic specificity. While the spectra of clinical presentations are similar between BV and MV individuals, BV carriers have a significantly earlier onset age. In BV individuals, total protein S (PS) and free PS levels, but not PS activity, show a correlation with the first-onset age. Notably, total PS in type III MV individuals is well correlated with their first-onset age, and these cases show a significantly lower frequency of symptoms and recurrent/multiple episodes, as well as later first-onset age. Furthermore, coexistence of other thrombophilia factors increases thrombosis risk of MV individuals.
CONCLUSION: This database provided a valuable resource for retrieving pathogenic PROS1 variants and associated clinical data, enhancing our understanding of thrombotic risk in PSD and facilitating precision medicine for PSD.